Huma Qamar, MD, MPH, CMI

Ocugen will host a live webcast Mar 24 at 8 a.m. EDT on Phase 2 ArMaDa data for #OCU410 in GA, led by KOLs Lejla Vajzovic, MD, and Jay Chhablani, MD. Don’t miss key insights into advancements in modifier gene therapy for retinal disease. Details: bit.ly/4uJ8GgG

Celebrating the 115th anniversary of #InternationalWomensDay. We recognize the women of Ocugen whose expertise, leadership, and dedication help advance innovation and our mission to deliver transformative novel modifier gene therapies to patients. #IWD2026 #GiveToGain

Enrollment is now complete for the Phase 3 liMeliGhT trial of #OCU400 for #retinitispigmentosa, the first and largest gene therapy registrational trial for broad RP patients. Ocugen remains on track to file a rolling BLA in 3Q 2026. #Biotech Read more: bit.ly/4lcvktK

We support @RareDiseaseDay! At Ocugen, we are committed to advancing our novel modifier gene therapies for rare inherited retinal diseases with significant unmet needs. We stand with patients, families, and the global #raredisease community, today and every day.

Dr. Gonzalez will present “Safety and Preliminary Efficacy of OCU410ST for Stargardt Disease: Phase 1 Results Update” at the 49th Annual Macula Society Meeting on behalf of Ocugen on Friday, Feb 27, 2026 from 7–7:05 a.m. PST. #GeneTherapy Learn more: bit.ly/4ruCf3R

During #RetinitisPigmentosaAwarenessMonth, the need for new treatments is clear. We are advancing #OCU400, our lead modifier gene therapy candidate, and plan to begin the BLA submission this year. Learn about Manny’s journey: bit.ly/4aQL9Bw #GeneTherapy #Biotech

Phase 2 #ArMaDa trial: OCU410 showed a 57% reduction in medium dose and 56% reduction in high dose in lesion growth in patients with baseline GA ≥7.5 mm², suggesting strong benefit in those with more advanced disease. #AMDAwarenessMonth @PBA_savingsight🔗bit.ly/3ZHoMsY

Today is International Day of Women and Girls in Science. Let’s work together to build a bright future for women and girls in STEM, celebrating those driving discovery today while encouraging the next generation of female scientists. #February11 #CourageousInnovation

Ocugen announced today the publication of Phase 1 GARDian1 trial data for #OCU410ST in @Eye_Journal. Results show favorable safety and tolerability with meaningful benefits in #Stargardtdisease after 12 months. Read more: bit.ly/4pzs0cE

Early dedication is critical when treating IRDs. Hear @davidalmeidaMD, a study investigator in the pivotal Phase 2/3 #OCU410ST clinical trial for #Stargardtdisease, discuss bridging the gap and treating patients. Enrollment is open in the GARDian3 trial. 📞484-224-3409

Ocugen’s LDNA mobility course is featured in @OTEurope! An FDA-accepted endpoint in the U.S., LDNA is a sensitive and specific way to measure meaningful daily function in IRD #clinicaltrials. Read: bit.ly/4b5k5Qv #IRDs #GeneTherapy

It’s #GeographicAtrophyAwarenessWeek. GA is a leading cause of irreversible vision loss in older adults. #OCU410 has shown improved visual acuity and slower lesion growth and has potential to treat patients with GA with a single, one-time therapy for life. @PBA_savingsight #dAMD